TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) Gross margin 2016–2025
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) gross margin by fiscal year — reported gross profit divided by reported revenue.
51.8%FY2025 · since FY2016: 53.2% → 51.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 51.8% | +3.0 pp |
| FY2024 | 48.7% | +0.5 pp |
| FY2023 | 48.2% | +1.5 pp |
| FY2022 | 46.7% | -1.1 pp |
| FY2021 | 47.8% | +1.4 pp |
| FY2020 | 46.4% | +1.7 pp |
| FY2019 | 44.6% | -0.8 pp |
| FY2018 | 45.4% | -3.2 pp |
| FY2017 | 48.6% | -4.6 pp |
| FY2016 | 53.2% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TEVA financial trends
TEVA RevenueTEVA Net incomeTEVA Net marginTEVA Gross profitTEVA Operating incomeTEVA Operating marginTEVA Operating cash flowTEVA Free cash flowTEVA Capital expendituresTEVA Return on equityTEVA Stock buybacksTEVA Dividends paidTEVA Total assetsTEVA Total liabilitiesTEVA Shareholders’ equityTEVA overview →